The Atossa Therapeutics Inc (NASDAQ:ATOS) stock has emerged as one of the notable gainer over the course of the past 6 weeks and has managed to clock gains of 130% in the period.
The company is involved in the biopharmaceutical space and is currently involved in discovering innovating products in the field of oncology as well as for tackling infectious diseases. Last month the company announced its financial results for the first quarter and did not report any source of sustainable revenues.
On the other hand, as of the end of the quarter on March 31, 2021, the company reported cash, restricted cash and cash equivalents to the tune of $137.7 million.
The operating expenses for the first quarter came in at $3,531,000. In the prior year period, the total operating expenses had been $2,937,000. The company had also hosted its anneal stockholder meeting back on May 14, 2021 and urged the participants to vote on the different proposals.
Market Action:
At the time of writing, ATOS stock soared 42 cents or 13% to $3.64. The stock has seen a total volume of 8.50 million shares, compared to its average volume of 10.99 million shares.
 Stock Sees Further Buying Pressure: A New Breakout?){kind=link}